NYSEReal EstateReal Estate - ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RFL yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
finalize partnership with India | Despite a 50% revenue drop in Q3 FY2026, a partnership with India could boost growth. | Improving | no partnership agreement signed within 12 months | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative development-stage biotech, not a durable earnings compounder today. The long-term thesis is in a watch state: management has submitted the Trappsol Cyclo application, but the clinical evidence and recent financial performance remain weak.
The evidence snapshot provides no valuation or market-expectations data, so it is not possible to judge whether RFL is cheap, fair, or expensive versus peers, or what expectations are already reflected. The business is loss-making, which limits what earnings-based valuation evidence can show.
Near term, results may remain pressured: the latest financial performance is described as weak, and another miss could lead analysts to reduce estimates again. Management has reduced general and administrative expenses, but research and development spending rose, while reported revenue remained modest; the materials show an FDA filing milestone, not a commercial launch.
Over the multi-year view, the central question is whether the FDA process can advance despite the Phase 3 study missing its primary endpoint in the overall population. The thesis also depends on whether Trappsol Cyclo can gain meaningful commercial traction and whether expense growth can be managed; a continued earnings miss would add pressure.
RFL’s 1-to-3-year outlook rests on regulatory progress and eventual commercialization, while mixed clinical results, losses, and weak recent performance keep the thesis high risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Rafael Holdings Inc's published investment case. The stated target is EPS >= 0. |
| Broken |
| EPS remains negative through FY27 |
Diluted EPS: $-0.18 per share FY2026-Q4; GAAP. Published target: EPS >= 0. Annual target cannot be compared with a quarterly or TTM observation. Oct 29, 2026-0.18 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
revenue growth recovers above -10% YoY | A primary condition in Rafael Holdings Inc's published investment case. The stated target is >= -10% YoY revenue growth. | Broken | YoY revenue growth remains below -10% in FY27 | Revenue growth: -30.29% FY2026-Q4; GAAP. Published target: >= -10% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Oct 29, 2026-30.285714 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.